mTOR activation in medullary thyroid carcinoma with RAS mutation.
about
Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.Biomarker and Pathologic Predictors of Cutaneous Squamous Cell Carcinoma Aggressiveness.Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.Calcitonin receptor expression in medullary thyroid carcinomaSorafenib in the treatment of thyroid cancer.
P2860
mTOR activation in medullary thyroid carcinoma with RAS mutation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@en
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@nl
type
label
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@en
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@nl
prefLabel
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@en
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@nl
P2093
P50
P356
P1476
mTOR activation in medullary thyroid carcinoma with RAS mutation.
@en
P2093
Fernando Rodrigues
Joana Lyra
Vasco Pinto
P304
P356
10.1530/EJE-14-0389
P577
2014-08-27T00:00:00Z